CLINICAL TRIALS AND OBSERVATIONS Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

نویسندگان

  • Antonio Palumbo
  • Maria Teresa Ambrosini
  • Giulia Benevolo
  • Patrizia Pregno
  • Norbert Pescosta
  • Vincenzo Callea
  • Clotilde Cangialosi
  • Tommaso Caravita
  • Fortunato Morabito
  • Pellegrino Musto
  • Sara Bringhen
  • Patrizia Falco
  • Ilaria Avonto
  • Federica Cavallo
  • Mario Boccadoro
چکیده

1Divisione di Ematologia dell’Università di Torino, Azienda Ospedaliera (AO) S. Giovanni Battista, Turin, Italy; 2Ematologia, Azienda Ospedaliera San Giovanni Battista, Turin, Italy; 3Divisione di Ematologia, Ospedale Centrale, Bolzano, Italy; 4Divisione di Ematologia, Ospedali Riuniti, Reggio Calabria, Italy; 5Divisione di Ematologia e Trapianto di Midollo Osseo, Azienda Ospedaliera Cervello, Palermo, Italy; 6Cattedra e Divisione di Ematologia, Università Tor Vergata, Ospedale San Eugenio, Rome, Italy; 7Unità Ospedaliera Complessa (UOC) di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy; 8UOC di Ematologia e Trapianto di Cellule Staminali, Centro di Riferimento Oncologico Regionale (CROB), Rionero in Vulture, Italy

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL TRIALS AND OBSERVATIONS Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan- prednisone (VMP) in untreated multiple myeloma patients with renal impairment

Fortunato Morabito,1 Massimo Gentile,1 Carla Mazzone,1 Davide Rossi,2 Francesco Di Raimondo,3 Sara Bringhen,4 Roberto Ria,5 Massimo Offidani,6 Francesca Patriarca,7 Chiara Nozzoli,8 Maria Teresa Petrucci,9 Giulia Benevolo,10 Iolanda Vincelli,11 Tommasina Guglielmelli,12 Mariella Grasso,13 Roberto Marasca,14 Luca Baldini,15 Vittorio Montefusco,16 Pellegrino Musto,17 Nicola Cascavilla,18 Ignazio ...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

1Centre René Gauducheau, Nantes/St Herblain, France; 2Universita di Torino, Torino, Italy; 3Dana-Farber Cancer Institute, Boston, MA; 4Praxisklinik Dr Schlag, Würzburg, Germany; 5University of Athens, School of Medicine, Athens, Greece; 6Rabin Medical Center, Petah-Tiqva, Israel; 7University of Münster, Münster, Germany; 8Belgian Myeloma Study Group, Brussels, Belgium; 9Institute of Hematology ...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Anders Waage,1 Peter Gimsing,2 Peter Fayers,1,3 Niels Abildgaard,4 Lucia Ahlberg,5 Bo Björkstrand,6 Kristina Carlson,7 Inger Marie Dahl,8 Karin Forsberg,9 Nina Gulbrandsen,10 Einar Haukås,11 Øyvind Hjertner,1 Martin Hjorth,12 Torbjörn Karlsson,13 Lene Meldgaard Knudsen,14 Johan Lanng Nielsen,15 Olle Linder,16 Ulf-Henrik Mellqvist,17 Ingerid Nesthus,18 Jürgen Rolke,19 Maria Strandberg,20 Jon Hja...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study

This prospective study evaluated the risk of arterial thrombosis in 195 consecutive patients aged 18 to 65 years with newly diagnosed multiple myeloma (MM). All patients were treated with 3 cycles of VAD (vincristine, doxorubicin, and dexamethasone) or TAD (thalidomide-AD) or PAD (bortezomib-AD) in national trials, followed by high-dose melphalan and autologous stem cell transplantation. For a ...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Improved survival in multiple myeloma and the impact of novel therapies

Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2007